Amylyx (AMLX) Pharmaceuticals announced the first participant has been dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia, or PBH. The trial will evaluate avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation, in approximately 75 participants. Amylyx expects completion of recruitment in 2025, with topline data anticipated in the first half of 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Biotech Alert: Searches spiking for these stocks today
- Amylyx doses first participant in LUMINA trial
- Amylyx upgraded to Outperform from Neutral at Mizuho
- Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position
- Buy Rating for Amylyx Pharmaceuticals: Avexitide’s Potential in Post-Bariatric Surgery Market